AR086191A1 - Triazolopiridinas - Google Patents

Triazolopiridinas

Info

Publication number
AR086191A1
AR086191A1 ARP120101355A ARP120101355A AR086191A1 AR 086191 A1 AR086191 A1 AR 086191A1 AR P120101355 A ARP120101355 A AR P120101355A AR P120101355 A ARP120101355 A AR P120101355A AR 086191 A1 AR086191 A1 AR 086191A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
halo
nr8r7
group
Prior art date
Application number
ARP120101355A
Other languages
English (en)
Spanish (es)
Inventor
Kosemund Dirk Dr
Wengner Antje Margret Dra
Siemeister Gerhard Dr
Stckigt Detlef Dr
Lienau Philip Dr
Schirok Hartmut Dr
Briem Hans Dr
Schulze Volker Dr
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AR086191A1 publication Critical patent/AR086191A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP120101355A 2011-04-21 2012-04-20 Triazolopiridinas AR086191A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27

Publications (1)

Publication Number Publication Date
AR086191A1 true AR086191A1 (es) 2013-11-27

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101355A AR086191A1 (es) 2011-04-21 2012-04-20 Triazolopiridinas

Country Status (39)

Country Link
US (1) US20140120087A1 (enExample)
EP (1) EP2699575B1 (enExample)
JP (1) JP5989091B2 (enExample)
KR (1) KR20140025470A (enExample)
CN (1) CN103608350B (enExample)
AP (1) AP3491A (enExample)
AR (1) AR086191A1 (enExample)
AU (1) AU2012244859B2 (enExample)
CA (1) CA2833657A1 (enExample)
CL (1) CL2013003044A1 (enExample)
CO (1) CO6801751A2 (enExample)
CR (1) CR20130539A (enExample)
CY (1) CY1116439T1 (enExample)
DK (1) DK2699575T3 (enExample)
DO (1) DOP2013000244A (enExample)
EA (1) EA023766B1 (enExample)
EC (1) ECSP13013011A (enExample)
ES (1) ES2539265T3 (enExample)
GT (1) GT201300254A (enExample)
HR (1) HRP20150517T1 (enExample)
HU (1) HUE025496T2 (enExample)
IL (1) IL228704A0 (enExample)
JO (1) JO3040B1 (enExample)
MA (1) MA35049B1 (enExample)
ME (1) ME02143B (enExample)
MX (1) MX348783B (enExample)
MY (1) MY164939A (enExample)
PE (1) PE20141351A1 (enExample)
PH (1) PH12013502169A1 (enExample)
PL (1) PL2699575T3 (enExample)
PT (1) PT2699575E (enExample)
RS (1) RS54044B1 (enExample)
SA (1) SA112330466B1 (enExample)
SG (1) SG194003A1 (enExample)
SI (1) SI2699575T1 (enExample)
TW (1) TWI558703B (enExample)
UY (1) UY34034A (enExample)
WO (1) WO2012143329A1 (enExample)
ZA (1) ZA201308707B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
EP2872506A1 (en) * 2012-07-10 2015-05-20 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
JP2016520634A (ja) * 2013-06-07 2016-07-14 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジン
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
CN105246891A (zh) * 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
CA2981844A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE602005010876D1 (de) 2004-08-17 2008-12-18 Galderma Res & Dev Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
CA2662074A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
AR067562A1 (es) * 2007-07-18 2009-10-14 Novartis Ag Compuestos heterociclicos inhibidores de kinasa
WO2009024824A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
AU2008291075A1 (en) * 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EA201000797A1 (ru) * 2007-11-27 2011-02-28 Целльзом Лимитид Аминотриазолы в качестве ингибиторов pi3k
JP2012517971A (ja) * 2009-02-13 2012-08-09 フォーヴィア・ファーマシューティカルズ キナーゼ阻害薬としての[1,2,4]トリアゾロ[1,5−a]ピリジン類
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
EA201301181A1 (ru) 2014-08-29
DK2699575T3 (da) 2015-06-22
CA2833657A1 (en) 2012-10-26
HRP20150517T1 (hr) 2015-06-19
PE20141351A1 (es) 2014-11-01
NZ616456A (en) 2015-09-25
RS54044B1 (sr) 2015-10-30
ES2539265T3 (es) 2015-06-29
MY164939A (en) 2018-02-15
TW201245194A (en) 2012-11-16
IL228704A0 (en) 2013-12-31
SG194003A1 (en) 2013-11-29
AU2012244859A1 (en) 2013-10-31
CN103608350B (zh) 2015-11-25
HUE025496T2 (en) 2016-04-28
AP2013007182A0 (en) 2013-10-31
ZA201308707B (en) 2016-07-27
PL2699575T3 (pl) 2015-08-31
HK1190398A1 (zh) 2014-07-04
ECSP13013011A (es) 2013-12-31
ME02143B (me) 2015-10-20
MX348783B (es) 2017-06-28
CO6801751A2 (es) 2013-11-29
SA112330466B1 (ar) 2015-09-28
EP2699575B1 (en) 2015-03-25
DOP2013000244A (es) 2014-03-16
JP2014511887A (ja) 2014-05-19
AU2012244859B2 (en) 2017-06-08
JO3040B1 (ar) 2016-09-05
MA35049B1 (fr) 2014-04-03
EA023766B1 (ru) 2016-07-29
CY1116439T1 (el) 2017-02-08
WO2012143329A1 (en) 2012-10-26
KR20140025470A (ko) 2014-03-04
MX2013012289A (es) 2013-11-21
PH12013502169A1 (en) 2014-01-13
SI2699575T1 (sl) 2015-10-30
JP5989091B2 (ja) 2016-09-07
EP2699575A1 (en) 2014-02-26
CN103608350A (zh) 2014-02-26
PT2699575E (pt) 2015-07-29
CR20130539A (es) 2013-12-04
CL2013003044A1 (es) 2014-05-02
GT201300254A (es) 2015-09-01
AP3491A (en) 2015-12-31
UY34034A (es) 2012-11-30
US20140120087A1 (en) 2014-05-01
TWI558703B (zh) 2016-11-21

Similar Documents

Publication Publication Date Title
AR086191A1 (es) Triazolopiridinas
AR079166A1 (es) Triazolopiridinas
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR078888A1 (es) Derivados heterociclicos nitrogenados de bencimidazol-imidazol utiles para tratar infecciones por hvc y composiciones farmaceuticas que los comprenden.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR091023A1 (es) Inhibidores del nampt
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR036365A1 (es) 1,8-naftiridin-4(1h)-onas alquin-aril sustituidas y composiciones farmaceuticas que las contienen
AR081934A1 (es) Compuestos de triazolopiridinas sustituidas, una combinacion farmaceutica que los comprende y el uso de dichos compuestos en la preparacion de medicamentos
AR093740A1 (es) Amidas como inhibidores de pim
AR091093A1 (es) Tienopirimidinas
RU2014140735A (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AR082946A1 (es) Imidazopiridazinas sustituidas
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
CO6331437A2 (es) Compuestos de pirrolo[2,3-d]pirimidina
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR090589A1 (es) INHIBIDORES DE b-LACTAMASA ISOXAZOL
AR101106A1 (es) Inhibidores de tirosina quinasa de bruton
PE20151860A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd
AR075253A1 (es) Pirimidinas fusionadas, procesos de preparacion y composiciones farmaceuticas que los contiene.
RU2015121431A (ru) Замещенные производные индол-5-ола и их терапевтическое применение
AR091022A1 (es) Inhibidores del nampt

Legal Events

Date Code Title Description
FB Suspension of granting procedure